Fig. 1
Challenge design. ICI immune checkpoint inhibitor, PD-L1 programmed death ligand 1, TCR T-cell receptor, TMB tumor mutational burden
Fig. 1 | Journal of Translational Medicine
Challenge design. ICI immune checkpoint inhibitor, PD-L1 programmed death ligand 1, TCR T-cell receptor, TMB tumor mutational burden